Statute Details
- Title: Medicines (Good Manufacturing Practice Certificate) Regulations
- Act Code: MA1975-RG16
- Type: Subsidiary Legislation (SL)
- Authorising Act: Medicines Act (Chapter 176), Section 74
- Current version status: Current version as at 27 Mar 2026
- Legislative history (key amendments): Amended by S 30/2007, S 37/2013, S 99/2019, S 460/2022, S 491/2024
- Commencement: Not specified in the extract (historical commencement includes 1 Jun 2002 via SL 130/2002)
- Key provisions in the extract: Section 2 (definitions); Section 3 (application and issuance); Section 4 (fees and no refund)
What Is This Legislation About?
The Medicines (Good Manufacturing Practice Certificate) Regulations (“GMP Certificate Regulations”) set out the procedural and administrative framework for obtaining a Good Manufacturing Practice (“GMP”) Certificate in Singapore. In plain terms, the Regulations tell manufacturers how to apply for a certificate that confirms their manufacturing processes meet an approved GMP standard for medicinal products and/or active pharmaceutical ingredients (“APIs”).
GMP is a quality assurance system focused on how medicines are consistently produced and controlled to meet quality standards. The Regulations therefore support Singapore’s broader medicines regulatory regime by providing a formal mechanism for assessing conformity with GMP standards and issuing certificates that can be relied upon for regulatory and commercial purposes.
Although the Regulations are relatively short, they are legally significant because they operationalise the Medicines Act’s provisions relating to GMP certification. They also specify certificate validity periods and the fee structure, including a no-refund rule—issues that frequently arise in regulatory submissions, compliance planning, and disputes over administrative costs.
What Are the Key Provisions?
1. Definitions and the regulatory “standards” benchmark (Section 2)
Section 2 provides three core definitions that anchor the entire regulatory scheme:
- Active pharmaceutical ingredient: defined as any raw material used as an active ingredient in the manufacture of a medicinal product.
- GMP Certificate: a certificate relating to the manufacture of a medicinal product or an API, attesting to conformity with a GMP Standard.
- Good Manufacturing Practice Standard: refers to the Pharmaceutical Inspection Convention/Pharmaceutical Inspection Co-Operation Scheme (PIC/S) Guide to GMP for medicinal products or APIs (as applicable), or such other GMP standard approved by the licensing authority.
For practitioners, the practical takeaway is that the “standard” is not limited to a single fixed document; it is anchored to PIC/S GMP guides but can also be replaced or supplemented by other standards approved by the licensing authority. This matters when advising on compliance readiness, gap assessments, and the scope of what will be assessed during certification.
2. Application process and issuance discretion (Section 3)
Section 3 is the operational heart of the Regulations. It addresses (i) how an application must be made, (ii) what the licensing authority can do after receiving it, and (iii) the validity period of certificates.
Application form and manner (Section 3(1)): An application for a GMP Certificate must be made to the licensing authority in such form and manner as the licensing authority may require. This is a common regulatory drafting approach that gives the authority flexibility to prescribe application templates, supporting documents, and submission channels. From a legal practice perspective, this means that compliance advice should not only focus on substantive GMP readiness but also on strict adherence to procedural requirements (e.g., required forms, declarations, and evidence).
Assessment and issuance (Section 3(2)): Upon receipt, the licensing authority may assess whether the applicant has satisfactory conformity with a GMP Standard. If satisfied, the authority may issue a GMP Certificate to the manufacturer, subject to such terms and conditions as the licensing authority thinks fit.
This “may issue” and “subject to such terms and conditions as the licensing authority thinks fit” language is important. It indicates that issuance is not automatic upon submission; it depends on the authority’s assessment. It also signals that certificates may carry conditions—potentially including limitations on scope, manufacturing sites, product categories, or obligations to maintain compliance. Practitioners should therefore treat the certificate not merely as a binary approval but as a regulatory instrument that may impose ongoing compliance duties.
Validity period (Section 3(3)): The Regulations distinguish between certificates issued before 1 February 2013 and those issued on or after that date:
- If issued before 1 February 2013, validity is not exceeding 2 years from the certificate date.
- If issued on or after 1 February 2013, validity is not exceeding 3 years from the date the assessment (referred to in Section 3(2)) is completed.
For current practice, the second limb is the relevant one: certificates issued on or after 1 February 2013 can last up to three years, but crucially the clock runs from the completion of the assessment, not necessarily from the certificate issuance date. This can affect renewal planning and compliance timelines, particularly where assessments are delayed or where certificates are issued after the assessment report is finalised.
3. Fees and the no-refund rule (Section 4)
Section 4 sets out the fees payable for GMP certification. It is particularly relevant for budgeting, procurement, and disputes about administrative charges.
Application fee (Section 4(1)(a)): The fee on application for a GMP Certificate is $6,570.
Additional GMP Certificates without further assessment (Section 4(1)(b)): For each additional GMP Certificate that does not require further assessment of conformity with any GMP Standard, the fee is $220.
No refund (Section 4(2)): No refund shall be made in respect of any fee paid under Section 4(1). This is a strict provision. Even if an application is withdrawn, refused, or otherwise does not result in issuance, the fee is not refundable. Practitioners should therefore advise clients to conduct pre-submission readiness reviews and to clarify, where possible, whether additional certificates will trigger further assessment (and thus additional fees or different charges) before paying.
4. Interaction with the Medicines Act (Section 3 “for the purposes of section 22”)
Section 3(1) expressly states that the application is “for the purposes of section 22 of the Act.” While the extract does not reproduce the Medicines Act text, this cross-reference indicates that the Regulations are procedural/administrative in nature and implement the Act’s certification framework. In practice, lawyers should read the Regulations together with the Medicines Act provisions on GMP certification, licensing authority powers, and any consequences of operating without appropriate certification.
How Is This Legislation Structured?
The GMP Certificate Regulations are structured as a short set of provisions:
- Section 1 (Citation): provides the short title.
- Section 2 (Definitions): defines key terms including GMP Certificate and the GMP Standard benchmark.
- Section 3 (Application for GMP Certificate): sets out the application mechanism, the licensing authority’s assessment and issuance powers, and the validity period.
- Section 4 (Fees): prescribes the fee amounts for applications and additional certificates, and states that fees are non-refundable.
There are no “Parts” in the extract, and the Regulations appear to be limited to these core administrative matters.
Who Does This Legislation Apply To?
The Regulations apply to manufacturers seeking a GMP Certificate for the manufacture of medicinal products and/or active pharmaceutical ingredients. The certificate is issued to the manufacturer, and the assessment is directed at conformity with the applicable GMP Standard.
In practical terms, the Regulations are relevant to pharmaceutical manufacturers operating in Singapore and to manufacturers seeking certification for regulatory compliance purposes (including potentially for supply chains, product registrations, or export-related quality assurance). Because the licensing authority may impose terms and conditions, the Regulations also affect how manufacturers structure their compliance systems across sites and product lines.
Why Is This Legislation Important?
Although the GMP Certificate Regulations are brief, they play a critical role in Singapore’s medicines compliance ecosystem. A GMP Certificate is a formal attestation of manufacturing quality systems. For regulated businesses, it can be a prerequisite or a key supporting document for regulatory approvals and ongoing compliance.
From a legal risk perspective, the Regulations highlight three issues that practitioners should manage proactively:
- Substantive compliance against the correct GMP Standard: the GMP Standard is tied to PIC/S guides (or other approved standards). Advice should confirm which guide applies (medicinal products vs APIs) and whether any “other approved” standards are relevant.
- Procedural compliance in applications: Section 3(1) requires applications to be made in the form and manner required by the licensing authority. Missing documents or non-compliant submissions can delay assessment and affect validity planning.
- Commercial certainty on fees and renewals: Section 4’s fee amounts and the no-refund rule mean that clients should undertake readiness assessments before paying. Additionally, the validity period runs from assessment completion (for certificates issued on or after 1 February 2013), which should be factored into renewal calendars.
Finally, the discretion embedded in Section 3(2)—including the authority’s ability to issue certificates subject to terms and conditions—means that legal counsel should review any certificate conditions carefully. These conditions can become the basis for compliance obligations and potential enforcement consequences if not met.
Related Legislation
- Medicines Act (Chapter 176) — in particular, Section 22 (referenced in Section 3 of the Regulations) and Section 74 (authorising provision for these Regulations).
Source Documents
This article provides an overview of the Medicines (Good Manufacturing Practice Certificate) Regulations for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.